CN102300860B - 作为磷酸二酯酶10抑制剂的吡嗪类化合物 - Google Patents
作为磷酸二酯酶10抑制剂的吡嗪类化合物 Download PDFInfo
- Publication number
- CN102300860B CN102300860B CN200980154871.6A CN200980154871A CN102300860B CN 102300860 B CN102300860 B CN 102300860B CN 200980154871 A CN200980154871 A CN 200980154871A CN 102300860 B CN102300860 B CN 102300860B
- Authority
- CN
- China
- Prior art keywords
- benzo
- pyrazine
- alkyl
- phenyl
- imidazoles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*=*c1*(*=*)[n]c(**([Cn])=*C)*1 Chemical compound C*=*c1*(*=*)[n]c(**([Cn])=*C)*1 0.000 description 6
- TZKWYAWVWIFGGQ-UHFFFAOYSA-N BC(CC1)CCC11OCCO1 Chemical compound BC(CC1)CCC11OCCO1 TZKWYAWVWIFGGQ-UHFFFAOYSA-N 0.000 description 1
- NLBIGRSOSCNFSF-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1c1nccnc1Oc(cc1)ccc1C(c1nc(cccc2)c2[nH]1)=O)=O Chemical compound CC(C)(C)OC(N(C1)CC1c1nccnc1Oc(cc1)ccc1C(c1nc(cccc2)c2[nH]1)=O)=O NLBIGRSOSCNFSF-UHFFFAOYSA-N 0.000 description 1
- MEAZAXUDNCFOIG-FQEVSTJZSA-N CC(C)([C@H](CCC1)N1c1nccnc1Oc(cc1)ccc1Nc1nc(cccc2)c2[s]1)O Chemical compound CC(C)([C@H](CCC1)N1c1nccnc1Oc(cc1)ccc1Nc1nc(cccc2)c2[s]1)O MEAZAXUDNCFOIG-FQEVSTJZSA-N 0.000 description 1
- FAHWPTVPKLRUAR-UHFFFAOYSA-N CC1(C(C(CC2)=CCC2O)=O)NC(C=CCC2)=C2N1 Chemical compound CC1(C(C(CC2)=CCC2O)=O)NC(C=CCC2)=C2N1 FAHWPTVPKLRUAR-UHFFFAOYSA-N 0.000 description 1
- HLVNFOUDBPCEJA-UHFFFAOYSA-N CC1(C(C2)CN2C(C)=O)N=CC=NC1Oc(cc1)ccc1C(C1N(C)c2ccccc2N1)=O Chemical compound CC1(C(C2)CN2C(C)=O)N=CC=NC1Oc(cc1)ccc1C(C1N(C)c2ccccc2N1)=O HLVNFOUDBPCEJA-UHFFFAOYSA-N 0.000 description 1
- YHPGDJLXFOITAO-UHFFFAOYSA-N CC1N=C(c2cccnc2OC)C(Oc2ccc(C(c3nc(cccc4)c4[nH]3)O)cc2)=NC1 Chemical compound CC1N=C(c2cccnc2OC)C(Oc2ccc(C(c3nc(cccc4)c4[nH]3)O)cc2)=NC1 YHPGDJLXFOITAO-UHFFFAOYSA-N 0.000 description 1
- PJRGIPZCWUCSGF-UHFFFAOYSA-N CCOC(c1nccnc1Oc(cc1)ccc1C(c1nc2ccccc2[nH]1)=O)=O Chemical compound CCOC(c1nccnc1Oc(cc1)ccc1C(c1nc2ccccc2[nH]1)=O)=O PJRGIPZCWUCSGF-UHFFFAOYSA-N 0.000 description 1
- ROZAUDGDBWPBMH-UHFFFAOYSA-N CN(c1nc(cccc2)c2[s]1)c(cc1)ccc1Oc1c(C2CCOCC2)nccn1 Chemical compound CN(c1nc(cccc2)c2[s]1)c(cc1)ccc1Oc1c(C2CCOCC2)nccn1 ROZAUDGDBWPBMH-UHFFFAOYSA-N 0.000 description 1
- MPJTUNCSDXXZHO-UHFFFAOYSA-N COC(C1(CCOCC1)c(nccn1)c1Cl)=O Chemical compound COC(C1(CCOCC1)c(nccn1)c1Cl)=O MPJTUNCSDXXZHO-UHFFFAOYSA-N 0.000 description 1
- FUEOBZKOZCKVDA-UHFFFAOYSA-N COCC(N(CC1)CCC1c1nccnc1OC(C=C1)=CCC1C(C(N(C12)C=[IH])=NC1C=CCC2O)=O)=O Chemical compound COCC(N(CC1)CCC1c1nccnc1OC(C=C1)=CCC1C(C(N(C12)C=[IH])=NC1C=CCC2O)=O)=O FUEOBZKOZCKVDA-UHFFFAOYSA-N 0.000 description 1
- ZIFHWMCIMSKRRO-UHFFFAOYSA-N Cc(nccn1)c1Oc(cc1)ccc1Nc1nc(ccc(F)c2)c2[s]1 Chemical compound Cc(nccn1)c1Oc(cc1)ccc1Nc1nc(ccc(F)c2)c2[s]1 ZIFHWMCIMSKRRO-UHFFFAOYSA-N 0.000 description 1
- DWGXKRSIXFWWNR-UHFFFAOYSA-N Cc1c(C(CC2)CCC2=O)nccn1 Chemical compound Cc1c(C(CC2)CCC2=O)nccn1 DWGXKRSIXFWWNR-UHFFFAOYSA-N 0.000 description 1
- LKUNBCKPUBIUEJ-UHFFFAOYSA-N FC1(CCOCC1)c(nccn1)c1F Chemical compound FC1(CCOCC1)c(nccn1)c1F LKUNBCKPUBIUEJ-UHFFFAOYSA-N 0.000 description 1
- MIBAZOPYQCXZIB-UHFFFAOYSA-N FCCN(CC1)CCC1c(nccn1)c1F Chemical compound FCCN(CC1)CCC1c(nccn1)c1F MIBAZOPYQCXZIB-UHFFFAOYSA-N 0.000 description 1
- PJNZDSRFOFFPQZ-UHFFFAOYSA-N Fc1c(C2CCOCC2)nccn1 Chemical compound Fc1c(C2CCOCC2)nccn1 PJNZDSRFOFFPQZ-UHFFFAOYSA-N 0.000 description 1
- CBTCHLZKZTYQSJ-UHFFFAOYSA-N O=C(c1nc(cccc2)c2[nH]1)c(cc1)ccc1Oc1nccnc1C1CCN(CCF)CC1 Chemical compound O=C(c1nc(cccc2)c2[nH]1)c(cc1)ccc1Oc1nccnc1C1CCN(CCF)CC1 CBTCHLZKZTYQSJ-UHFFFAOYSA-N 0.000 description 1
- NVZBDCOGNZHANV-UHFFFAOYSA-N O=C(c1nc(cccc2)c2[nH]1)c(cc1)ccc1Oc1nccnc1C1CCOCCC1 Chemical compound O=C(c1nc(cccc2)c2[nH]1)c(cc1)ccc1Oc1nccnc1C1CCOCCC1 NVZBDCOGNZHANV-UHFFFAOYSA-N 0.000 description 1
- YWFDAAMTUBHJGI-UHFFFAOYSA-N O=C(c1nc(cccc2)c2[nH]1)c(cc1)ccc1Oc1nccnc1N1CCOCC1 Chemical compound O=C(c1nc(cccc2)c2[nH]1)c(cc1)ccc1Oc1nccnc1N1CCOCC1 YWFDAAMTUBHJGI-UHFFFAOYSA-N 0.000 description 1
- PYCDSETUWLDZCK-UHFFFAOYSA-N OC(CCC1)C=C1c1nccnc1Oc(cc1F)ccc1Nc1nc(cccc2)c2[s]1 Chemical compound OC(CCC1)C=C1c1nccnc1Oc(cc1F)ccc1Nc1nc(cccc2)c2[s]1 PYCDSETUWLDZCK-UHFFFAOYSA-N 0.000 description 1
- ULGMGAHWUJJCLB-UHFFFAOYSA-N Oc(cc1)ccc1C(c1nc(cccc2)c2[nH]1)=O Chemical compound Oc(cc1)ccc1C(c1nc(cccc2)c2[nH]1)=O ULGMGAHWUJJCLB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11456708P | 2008-11-14 | 2008-11-14 | |
| US61/114567 | 2008-11-14 | ||
| US61/114,567 | 2008-11-14 | ||
| US16621209P | 2009-04-02 | 2009-04-02 | |
| US61/166212 | 2009-04-02 | ||
| US61/166,212 | 2009-04-02 | ||
| PCT/US2009/064637 WO2010057121A1 (en) | 2008-11-14 | 2009-11-16 | Pyrazine compounds as phosphodiesterase 10 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102300860A CN102300860A (zh) | 2011-12-28 |
| CN102300860B true CN102300860B (zh) | 2014-08-27 |
Family
ID=41478512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980154871.6A Expired - Fee Related CN102300860B (zh) | 2008-11-14 | 2009-11-16 | 作为磷酸二酯酶10抑制剂的吡嗪类化合物 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US8053438B2 (enExample) |
| EP (1) | EP2364308B1 (enExample) |
| JP (1) | JP5746972B2 (enExample) |
| KR (1) | KR20110083746A (enExample) |
| CN (1) | CN102300860B (enExample) |
| AR (1) | AR074358A1 (enExample) |
| AU (1) | AU2009313768B2 (enExample) |
| BR (1) | BRPI0922095A2 (enExample) |
| CA (1) | CA2742993C (enExample) |
| CL (1) | CL2011001094A1 (enExample) |
| CO (1) | CO6382157A2 (enExample) |
| CR (1) | CR20110326A (enExample) |
| CY (1) | CY1113680T1 (enExample) |
| DK (1) | DK2364308T3 (enExample) |
| EA (1) | EA019206B1 (enExample) |
| ES (1) | ES2397218T3 (enExample) |
| HR (1) | HRP20130054T1 (enExample) |
| IL (1) | IL212687A0 (enExample) |
| MA (1) | MA32889B1 (enExample) |
| MX (1) | MX2011005100A (enExample) |
| NZ (1) | NZ592508A (enExample) |
| PE (1) | PE20110581A1 (enExample) |
| PL (1) | PL2364308T3 (enExample) |
| PT (1) | PT2364308E (enExample) |
| RS (1) | RS52598B (enExample) |
| SI (1) | SI2364308T1 (enExample) |
| SM (1) | SMT201200061B (enExample) |
| TN (1) | TN2011000221A1 (enExample) |
| TW (1) | TWI396689B (enExample) |
| WO (1) | WO2010057121A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| JP2012512255A (ja) * | 2008-12-17 | 2012-05-31 | アムジエン・インコーポレーテツド | ホスホジエステラーゼ１０阻害剤としてのアミノピリジンおよびカルボキシピリジン化合物 |
| US8354411B2 (en) | 2009-02-05 | 2013-01-15 | Takeda Pharmaceutical Company Limited | 1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound |
| WO2010132442A1 (en) * | 2009-05-12 | 2010-11-18 | Albany Molecular Reserch, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
| WO2010132487A1 (en) | 2009-05-12 | 2010-11-18 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
| JP5780528B2 (ja) | 2010-02-19 | 2015-09-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 三環式ピリジン誘導体、このような化合物を含有する医薬、それらの使用、およびそれらの調製方法 |
| WO2011163355A1 (en) | 2010-06-24 | 2011-12-29 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors |
| WO2012018058A1 (ja) | 2010-08-04 | 2012-02-09 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| US9029536B2 (en) | 2010-08-04 | 2015-05-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| US9150588B2 (en) | 2010-08-10 | 2015-10-06 | Takeda Pharmaceutical Company Limited | Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors |
| EP3357915A1 (en) | 2010-11-19 | 2018-08-08 | Ligand Pharmaceuticals Inc. | Heterocycle amines with anti-inflammatory activity |
| WO2012096929A2 (en) | 2011-01-11 | 2012-07-19 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| US9029388B2 (en) | 2011-03-16 | 2015-05-12 | Takeda Pharmaceutical Company Limited | Condensed heterocyclic compound |
| TWI570122B (zh) | 2011-06-22 | 2017-02-11 | 武田藥品工業股份有限公司 | 稠合雜環化合物之結晶 |
| EP2890370B1 (en) * | 2012-08-31 | 2019-10-09 | The Regents of the University of California | Agents useful for treating obesity, diabetes and related disorders |
| CN102911135B (zh) * | 2012-10-18 | 2016-01-13 | 内蒙古工业大学 | 2-巯基苯并噻唑类衍生物的合成方法 |
| WO2014123899A1 (en) | 2013-02-05 | 2014-08-14 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| WO2014142322A1 (ja) | 2013-03-15 | 2014-09-18 | 第一三共株式会社 | ベンゾチオフェン誘導体 |
| US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
| KR20160092991A (ko) | 2013-09-27 | 2016-08-05 | 님버스 아이리스 인코포레이티드 | Irak 억제제 및 이의 용도 |
| US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| CN104649882A (zh) * | 2015-02-11 | 2015-05-27 | 南通恒盛精细化工有限公司 | 一种磷酸二酯酶抑制剂的中间体制备工艺 |
| US10807983B2 (en) | 2015-03-16 | 2020-10-20 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
| KR20180052635A (ko) * | 2015-09-18 | 2018-05-18 | 가켄 세이야쿠 가부시키가이샤 | 바이아릴 유도체 및 이를 포함하는 약제 |
| US11453674B2 (en) | 2018-01-19 | 2022-09-27 | Evopoint Biosciences Co., Ltd. | Heterocyclic compound, preparation method and use thereof in medicine |
| CN109020977B (zh) * | 2018-10-26 | 2020-11-13 | 安庆奇创药业有限公司 | 一种Acalabrutinib的制备方法 |
| CN116583577B (zh) | 2020-12-17 | 2025-10-21 | 默克专利股份有限公司 | 杂芳族异硫氰酸酯 |
| CN113929598A (zh) * | 2021-11-24 | 2022-01-14 | 上海吉奉生物科技有限公司 | 一种（s）-2-叔丁氧羰基氨基-3-（4,4-二氟环己基）丙酸的合成方法 |
| WO2023217156A1 (zh) * | 2022-05-09 | 2023-11-16 | 浙江同源康医药股份有限公司 | 多环类化合物及其用途 |
| CN115894181A (zh) * | 2022-09-30 | 2023-04-04 | 渭南高新区海泰新型电子材料有限责任公司 | 一种环己烯基环己基二氟苯类液晶化合物的合成方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007129183A2 (en) * | 2006-05-02 | 2007-11-15 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
| WO2008084299A1 (en) * | 2006-12-21 | 2008-07-17 | Pfizer Products Inc. | Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4198417A (en) | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenoxyphenylpiperidines |
| ATE392896T1 (de) | 2003-04-04 | 2008-05-15 | Lundbeck & Co As H | 4-(2-phenyloxyphenyl)-piperidin- oder -1,2,3,6- tetrahydropyridin-derivate als serotonin- wiederaufnahme-hemmer |
| DE10337942A1 (de) | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
| DE10344223A1 (de) | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
| DE10349587A1 (de) | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
| US7470712B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| KR100907354B1 (ko) * | 2004-05-18 | 2009-07-10 | 쉐링 코포레이션 | Ｐｄｅ4 억제제로서 유용한 치환된 2-퀴놀릴-옥사졸 |
| WO2005120514A1 (en) * | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| DE102005016634A1 (de) | 2005-04-12 | 2006-10-19 | Merck Patent Gmbh | Neuartige Aza-Hetercyclen als Kinase-Inhibitoren |
| US20080227783A1 (en) | 2005-08-02 | 2008-09-18 | Irm Llc | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors |
| WO2007098169A1 (en) * | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| US7868177B2 (en) | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| US20080090834A1 (en) * | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| WO2008057280A1 (en) | 2006-10-27 | 2008-05-15 | Amgen Inc. | Multi-cyclic compounds and methods of use |
| KR20100089090A (ko) | 2007-10-25 | 2010-08-11 | 아스트라제네카 아베 | 세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체 |
| WO2009081259A1 (en) | 2007-12-21 | 2009-07-02 | Pfizer Inc. | Phenoxy-pyridyl derivatives |
| KR20110026481A (ko) | 2008-06-20 | 2011-03-15 | 메타볼렉스, 인코포레이티드 | 아릴 ｇｐｒ１１９ 작동약 및 이의 용도 |
-
2009
- 2009-11-13 TW TW098138718A patent/TWI396689B/zh not_active IP Right Cessation
- 2009-11-16 EP EP09752705A patent/EP2364308B1/en active Active
- 2009-11-16 NZ NZ592508A patent/NZ592508A/xx not_active IP Right Cessation
- 2009-11-16 WO PCT/US2009/064637 patent/WO2010057121A1/en not_active Ceased
- 2009-11-16 CN CN200980154871.6A patent/CN102300860B/zh not_active Expired - Fee Related
- 2009-11-16 BR BRPI0922095A patent/BRPI0922095A2/pt not_active IP Right Cessation
- 2009-11-16 KR KR1020117013506A patent/KR20110083746A/ko not_active Withdrawn
- 2009-11-16 AR ARP090104436A patent/AR074358A1/es not_active Application Discontinuation
- 2009-11-16 DK DK09752705.5T patent/DK2364308T3/da active
- 2009-11-16 EA EA201100748A patent/EA019206B1/ru not_active IP Right Cessation
- 2009-11-16 PL PL09752705T patent/PL2364308T3/pl unknown
- 2009-11-16 JP JP2011536567A patent/JP5746972B2/ja not_active Expired - Fee Related
- 2009-11-16 AU AU2009313768A patent/AU2009313768B2/en not_active Ceased
- 2009-11-16 PT PT97527055T patent/PT2364308E/pt unknown
- 2009-11-16 ES ES09752705T patent/ES2397218T3/es active Active
- 2009-11-16 SI SI200930429T patent/SI2364308T1/sl unknown
- 2009-11-16 CA CA2742993A patent/CA2742993C/en not_active Expired - Fee Related
- 2009-11-16 US US12/619,574 patent/US8053438B2/en not_active Expired - Fee Related
- 2009-11-16 RS RS20120569A patent/RS52598B/sr unknown
- 2009-11-16 HR HRP20130054AT patent/HRP20130054T1/hr unknown
- 2009-11-16 MX MX2011005100A patent/MX2011005100A/es active IP Right Grant
- 2009-11-16 PE PE2011001035A patent/PE20110581A1/es not_active Application Discontinuation
-
2011
- 2011-03-07 US US13/042,410 patent/US8329700B2/en not_active Expired - Fee Related
- 2011-03-07 US US13/042,421 patent/US8247418B2/en not_active Expired - Fee Related
- 2011-05-04 IL IL212687A patent/IL212687A0/en unknown
- 2011-05-05 TN TN2011000221A patent/TN2011000221A1/fr unknown
- 2011-05-13 CL CL2011001094A patent/CL2011001094A1/es unknown
- 2011-06-10 MA MA33928A patent/MA32889B1/fr unknown
- 2011-06-14 CR CR20110326A patent/CR20110326A/es not_active Application Discontinuation
- 2011-06-14 CO CO11073978A patent/CO6382157A2/es not_active Application Discontinuation
-
2012
- 2012-06-22 US US13/531,453 patent/US20120277209A1/en not_active Abandoned
- 2012-12-19 SM SM201200061T patent/SMT201200061B/it unknown
- 2012-12-21 CY CY20121101246T patent/CY1113680T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007129183A2 (en) * | 2006-05-02 | 2007-11-15 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
| WO2008084299A1 (en) * | 2006-12-21 | 2008-07-17 | Pfizer Products Inc. | Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102300860B (zh) | 作为磷酸二酯酶10抑制剂的吡嗪类化合物 | |
| EP2364306B1 (en) | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | |
| CN103221404B (zh) | 可用作pde10抑制剂的不饱和氮杂环化合物 | |
| US9376450B2 (en) | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | |
| CN114423753A (zh) | 作为cd38抑制剂的杂双环酰胺 | |
| AU2011253003A1 (en) | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | |
| WO2022155419A1 (en) | Indazoles and azaindazoles as lrrk2 inhibitors | |
| HK1161251B (en) | Pyrazine compounds as phosphodiesterase 10 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140827 Termination date: 20161116 |